The prevalence of counterfeit GLP-1 drugs is driven by poor insurance quality and a lack of access to affordable medication in the traditional system.

“I think there's always been counterfeit medicines. We're not used to it in the United States because we one have a for most people a pretty good system to subsidize some of the benefit via the insurance markets. So there's not a lot of incentive to go outside the system. That's different for these d”